Lilly osteoporosis drug recommended for breast cancer
A Food and Drug Administration advisory panel has recommended approving Eli Lilly and Co.’s Evista osteoporosis drug for cutting the risk of cancer in post-menopausal women with osteoporosis and post-menopausal women at high risk for breast cancer. The non-binding recommendation follows an announcement from Lilly earlier this month that Evista reduced the risk of certain […]